Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANIX
Strong SellSinkerAnixa Biosciences, Inc. · Healthcare · United States · $118M · Avg Vol: $727K/d
COMPANY DESCRIPTION
Anixa Biosciences, Inc. is a biotechnology company focused on the development of cancer vaccines and novel CAR-T immunotherapies. The company's competitive moat is driven by its strategic research collaborations with premier institutions like the Cleveland Clinic and its proprietary platform targeting tissue-specific proteins. It operates as an innovative developer of preventative cancer vaccines, particularly for breast and ovarian cancers.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0.2M | 0 | 0 | — | — | — | — | — |
| EPS | -0.45 | -0.32 | -0.39 | -0.34 | — | -0.30 | -0.31 | -0.31 | — |
| Shares | 30.9M | 31.1M | 32.2M | 33.0M | +6.8% | 34.0M | — | — | — |
| Debt | 0.2M | 0.2M | 0.2M | 0.2M | -2.6% | 0.2M | — | — | — |
| Equity | 29.0M | 24.3M | 20.0M | 15.2M | -19.5% | — | — | — | — |
| Op CF | -6.5M | -6.2M | -7.3M | -7.2M | — | -7.1M | — | — | — |
| Inv CF | -10.7M | -5.6M | 4.3M | 4.9M | — | — | — | — | — |
| Fin CF | 0.5M | 0.4M | 3.4M | 2.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANIX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANIX | Anixa Biosciences, Inc.(you) | $118M | 14 | Strong Sell |
| GUTS | Fractyl Health, Inc. | $105M | 14 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 16 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
| CGTX | Cognition Therapeutics, Inc. | $97M | 13 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| VTVT | vTv Therapeutics Inc. | $128M | 18 | Strong Sell |
| AARD | Aardvark Therapeutics, Inc. | $127M | 18 | Strong Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%